All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Quizartinib granted FDA approval for patients with newly diagnosed FLT3-ITD mutated AML
Bookmark this article
On July 20, 2023, quizartinib, an oral, highly potent and selective type II FLT3 inhibitor extensively covered by the AML Hub, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with newly diagnosed (ND) acute myeloid leukemia (AML) with FLT3-internal tandem duplication (FLT3-ITD) mutations.1
Quizartinib was previously granted priority review by the FDA. The FDA also approved LeukoStrat CDx FLT3 mutation assay as a companion diagnostic for quizartinib.1 Quizartinib was recently approved in Japan for the treatment of patients with ND FLT3-ITD mutated AML.
FLT3 mutations occur in roughly 37% of ND AML patients; most commonly FLT3-ITD mutations (80%), and are associated with inferior survival outcomes.2 This approval is for use in combination with standard cytarabine and anthracycline induction, cytarabine consolidation, and as a maintenance monotherapy. Quizartinib is not currently indicated as maintenance monotherapy post-allogeneic hematopoietic stem cell transplantation.1
This approval is based on results from the randomized, double-blind, placebo-controlled, phase III QuANTUM-First trial (NCT02668653), which has been previously reported on by the AML Hub. In this trial, quizartinib in combination with cytarabine and anthracycline induction, cytarabine consolidation, and continued as maintenance monotherapy after consolidation, was associated with improved overall survival versus standard chemotherapy alone in patients with ND FLT3-ITD mutated AML (hazard ratio, 0.78; p = 0.0324). Complete remission rates were 55% for both treatment arms; however, quizartinib was associated with a longer median duration of complete remission when compared with standard chemotherapy alone (38.6 months vs 12.4 months, respectively).1
Quizartinib comes with a Boxed Warning for QT prolongation, torsades de pointes, and cardiac arrest, and is only available through a restricted program under a Risk Evaluation and Mitigation Strategy.1
- U.S. Food and Drug Administration. FDA approves quizartinib for newly diagnosed acute myeloid leukemia. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-quizartinib-newly-diagnosed-acute-myeloid-leukemia. Published Jul 20, 2023. Accessed Jul 21, 2023.
- Daiichi Sankyo. VANFLYTA® First FLT3 inhibitor approved in the U.S. specifically for patients with newly diagnosed FLT3-ITD positive AML. https://www.daiichisankyo.com/files/news/pressrelease/pdf/202307/20230720_E.pdf. Published Jul 20, 2023. Accessed Jul 21, 2023.
Newsletter
Subscribe to get the best content related to AML delivered to your inbox